Toggle light / dark theme

Moderna seeks FDA authorization for 4th dose of COVID shot

WASHINGTON (AP) — Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults.

The request is broader than rival pharmaceutical company Pfizer’s request earlier this week for the regulator to approve a booster shot for all seniors.

In a press release, the company said its request for approval for all adults was made “to provide flexibility” to the Centers for Disease Control and Prevention and medical providers to determine the “appropriate use” of a second booster dose of the mRNA vaccine, “including for those at higher risk of COVID-19 due to age or comorbidities.”

Self-assembling and complex, nanoscale mesocrystals can be tuned for a variety of uses

A research team from KTH Royal Institute of Technology and Max Planck Institute of Colloids and Interfaces reports to have found the key to controlled fabrication of cerium oxide mesocrystals. The research is a step forward in tuning nanomaterials that can serve a wide range of uses—including solar cells, fuel catalysts and even medicine.

Mesocrystals are nanoparticles with identical size, shape and crystallographic orientation, and they can be used as to create artificial nanostructures with customized optical, magnetic or electronic properties. In nature, these three-dimensional structures are found in coral, sea urchins and calcite desert rose, for example. Artificially-produced cerium oxide (CeO2) mesocrystals—or nanoceria—are well-known as catalysts, with antioxidant properties that could be useful in pharmaceutical development.

“To be able to fabricate CeO2 mesocrystals in a controlled way, one needs to understand the formation mechanism of these materials,” says Inna Soroka, a researcher in applied at KTH. She says the team used radiation chemistry to reveal for the first time the ceria mesocrystal formation mechanism.

Katie Baca-Motes — Co-Founder, Scripps Research Digital Trials Ctr — Re-Engineering Clinical Trials

Re-engineering clinical trials around participants — katie baca-motes, co-founder, scripps research digital trials center, scripps research.


Katie Baca-Motes, MBA, (https://www.scripps.edu/science-and-medicine/translational-i…aca-motes/) is Senior Director, Strategic Initiatives at the Scripps Research Translational Institute, and Co-Founder of the Scripps Research Digital Trials Center (https://digitaltrials.scripps.edu/).

Katie leads various initiatives, including launching their new Digital Trials Center, focusing on expanding the institute’s portfolio of decentralized clinical trial initiatives including: DETECT, a COVID-19 research initiative, PowerMom, a maternal health research program and PROGRESS, an upcoming T2 Diabetes/Precision Nutrition program, as well as overseeing the institute’s role in the NIH “All of Us” Research Program as a Participant Center.

The Scripps Research Translational Institute (SRTI), was founded in 2007 with the aim of individualizing healthcare by leveraging the remarkable progress being made in human genomics and combining it with the power of wireless digital technologies.

The Scripps Research Digital Trials Center, a part of SRTI, leads groundbreaking studies that address the world’s most pressing health concerns, by pioneering “site-less” clinical trials, leveraging rapidly evolving digital health technologies to re-engineer the clinical trial experience around the participant, rather than the research site.

Will your digital twin make you healthier? | Jacqueline Alderson | TEDxPerth

Would you share your data for the common good? Biomechanist Jacqueline Alderson shows how sophisticated simulations based on real data can help prevent disease, illness and injury. Jacqueline Alderson is an Associate Professor of Biomechanics at the University of Western Australia and Adjunct Professor of Human Performance, Innovation and Technology at the Auckland University of Technology. She has always been curious about movement — whether it’s helping surgeons make best practice decisions or helping AFL players avoid knee injuries. She now travels the world to share her knowledge in human movement, wearable tech and artificial intelligence and its role in tracking, analysing and intervening in the human condition. This talk was given at a TEDx event using the TED conference format but independently organized by a local community.

Protein subunit COVID vaccine, which can be manufactured using engineered yeast, shows promise in preclinical studies

While many people in wealthier countries have been vaccinated against COVID-19, there is still a need for vaccination in much of the world. A new vaccine developed at MIT and Beth Israel Deaconess Medical Center may aid in those efforts, offering an inexpensive, easy-to-store, and effective alternative to RNA vaccines.

In a new paper, the researchers report that the vaccine, which comprises fragments of the SARS-CoV-2 spike arrayed on a virus-like particle, elicited a strong immune response and protected animals against viral challenge.

The vaccine was designed so that it can be produced by yeast, using fermentation facilities that already exist around the world. The Serum Institute of India, the world’s largest manufacturer of vaccines, is now producing large quantities of the vaccine and is running a clinical trial in Africa.

Wax-coated sand keeps soil wet longer, improves crop yields in arid regions

Dry, hot regions are difficult places to grow plants because the soil dries out quickly. As a result, farmers in arid and semi-arid regions irrigate their fields with buried networks of irrigation tubing and cover the ground with plastic sheets. But plastic sheets are expensive and create waste. Now, researchers reporting in ACS Agricultural Science & Technology have developed a simple, biodegradable ground cover—wax-coated sand—which keeps soil wet and increases crop yields.

To irrigate crops, farmers usually get water from nearby waterways or underground aquifers. These supplies can be rapidly depleted when growing plants in , where the soil is comprised mostly of sand and can’t hold onto water well. One way to improve irrigated water’s efficiency is to make sure it stays in the soil long enough so that plants’ roots can take it up. Previous studies have shown that ground cover barriers, such as plastic sheets and engineered nanomaterials, can slow evaporation and enhance and . However, both could leach unwanted compounds into the soil with unknown long-term impacts. Some plants and animals naturally produce waxy substances that trap and pool water from fog or condensation so that they can access these moisture sources. Taking inspiration from nature, Himanshu Mishra and colleagues wanted to see if they could coat sand with wax, creating an environmentally benign ground cover to control soil evaporation.

The researchers chose purified paraffin wax, a biodegradable substance available in large quantities, for their experiments. They dissolved the wax in hexane and poured silica sand into the mixture. As the solvent evaporated, a 20-nm-thick coating of wax was left behind on the grains. When the team applied the wax-coated sand in a on an open field in Saudi Arabia, it decreased the loss of soil moisture up to 50–80%. Field trials revealed that tomato, barley and wheat plants mulched with the new material produced substantially more fruit and grain than those grown in uncovered soil. In addition, the microbial community around the plants’ roots and in the soil wasn’t negatively impacted by the waxy mulch, which could have acted as a food source for some of the microbes. This simple nature-inspired technology could make more efficient in arid regions, the researchers say.

Can We Resurrect Extinct Species? Scientists Put Jurassic Park to the Test

De-extinction grabbed our imagination in the 90s with Jurassic Park. Scientists have since asked: how possible is it?

According to a new study, nearly impossible. But wait—it’s not all bad news. While bringing back a faithful copy of an extinct species may be impossible, we could bring back a hybrid species that’s a genetic mix between an extinct species and its modern descendant.

Published in Current Biology, the study eschews the grandiose mammoth, instead focusing on a tiny test case: the Christmas Island rat. Hefty in size and loudly vocal when invading docked ships and their cargo, the rodents were last seen in the 1900s. With a stroke of luck, the team recovered DNA from two well-preserved museum samples and compared them against a close relative: the Norway brown rat, a popular lab model for genetic studies today.

DocGo unveils first all-electric, zero-emission ambulance in the U.S.

The last-mile mobile health services provider, DocGo, has announced the delivery of its new all-electric, zero-emissions ambulance that eliminates the pollution of a standard gasoline ambulance.

The all–electric vehicle will be the first of its kind to be registered in the U.S. The new vehicle has been developed in partnership with Leader Emergency Vehicles in South El Monte, CA, and marks the first step towards “Zero Emission,” the company’s latest sustainability mission to have an all-electric fleet by 2032.

DocGo stated that its new vehicle produces 1/10th of the pollutants expelled by a standard gas-powered ambulance. In addition to being less harmful to the planet, the electric ambulance has the potential to lower patient transportation costs due to lower fuel costs and maintenance needs.

/* */